Tabernero, J., Bekaii-Saab, T., Safont Aguilera, M., Cubillo, A., Garcia-Carbonero, R., Limon, L., … López-López, C. (2021). P-111 PERSPECTIVE: Tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplification. In Annals of Oncology (Vol. 32, pp. S136–S137). Elsevier BV. https://doi.org/10.1016/j.annonc.2021.05.166

Tabernero, J., T. Bekaii-Saab, M. Safont Aguilera, A. Cubillo, R. Garcia-Carbonero, L. Limon, N. Rodríguez-Salas, et al. “P-111 PERSPECTIVE: Tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplification.” In Annals of Oncology, 32:S136–37. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.05.166.

Tabernero J, Bekaii-Saab T, Safont Aguilera M, Cubillo A, Garcia-Carbonero R, Limon L, et al. P-111 PERSPECTIVE: Tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplification. In: Annals of Oncology. Elsevier BV; 2021. p. S136–7.

Tabernero, J., et al. “P-111 PERSPECTIVE: Tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplification.” Annals of Oncology, vol. 32, Elsevier BV, 2021, pp. S136–37. Crossref, doi:10.1016/j.annonc.2021.05.166.

Tabernero J, Bekaii-Saab T, Safont Aguilera M, Cubillo A, Garcia-Carbonero R, Limon L, Rodríguez-Salas N, Tournigand C, Borg C, Raghav K, Finley G, Strickler J, Beier F, Salim S, Esser R, Liu E, Adrian S, López-López C. P-111 PERSPECTIVE: Tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplification. Annals of Oncology. Elsevier BV; 2021. p. S136–S137.